Appendix.
Parameter | Coding | Coefficient | Standard Error | P Value** |
---|---|---|---|---|
Outcome: Symptomatic Infection | 1 = Symptomatic infection in active surveillance window (n = 34) | … | … | … |
0 = Subclinical infection in active surveillance window (n = 89) | ||||
Enrollment antibody profile (“Some_imm”) | 1 = HI-negative | 1.593 | 0.467 | <.001 |
0 = HI-negative | ||||
Two years post-1st infection† (“Time2”) | 1 = Infected in year 2 | 0.193 | 0.305 | .379 |
0 = Infected in year 1 or 3 | ||||
Three years post-1st infection (“Time3”) | 1 = Infected in year 3 | 0.195 | 0.391 | .734 |
0 = Infected in year 1 or 2 | ||||
Some_imm*Time2 | Interaction term for 2 years post-1st infection and immunity | 0.651 | 0.317 | .065 |
Some_imm*Time3 | Interaction term for 3 years post-1st infection and immunity | 0.921 | 0.385 | .011 |
Rise in summed HI titers following the 1st infection | 1 = Less than or equal to the mean | 0.643 | 0.317 | .040 |
0 = Greater than the mean |
Abbreviation: HI, hemagglutination inhibition.
* Conditioned on subdistrict of residence and study period of enrollment (KPS1 or KPS2).
** Exact P values were calculated.
† Year 4 was not assessed in this model because no subclinical infections occurred 4 years after the first.